Volume : 12, Issue : 11, November – 2025
Title:
A STUDY ON ASSESSMENT OF EFFICACY AND SAFETY OF URSODEOXYCHOLIC ACID IN PATIENTS WITH CHRONIC LIVER DISEASE
Authors :
Mr.Prajwal R Yallur, Chandana Basavaraj Sanadi
Abstract :
Background: Chronic liver disease (CLD) results in gradual liver failure and related health problems. UDCA, an acid derivative of bile, is offered as a protective measure for the liver, but still more trials are needed to determine its effectiveness and safety in cases of CLD. This study was conducted to evaluate the efficacy and safety of UDCA in patients suffering from chronic liver disease.
Methods: The study performed was a prospective observational one that accepted 80 CLD patients, of age between 18 and 70 years. All patients were treated with UDCA 300–600 mg/day for a period of 12 weeks. Clinical symptoms like jaundice, pruritus, fatigue, and abdominal pain as well as biochemical parameters comprising total bilirubin, albumin, AST, ALT, and ALP were monitored at baseline, 4 and 12 weeks. Safety was guaranteed by adverse event monitoring and laboratory evaluations.
Results: The therapy with UDCA resulted in a marked change in the liver function tests: the levels of ALT decreased from 108.2 ± 41.6 U/L to 62.5 ± 25.3 U/L; in the case of AST, the reduction was from 96.1 ± 37.2 U/L to 59.8 ± 21.5 U/L, while for ALP it was from 212.4 ± 80.3 U/L to 161.9 ± 63.2 U/L, and finally bilirubin decreased from 2.4 ± 1.2 mg/dL to 1.3 ± 0.7 mg/dL (p<0.05). Clinical symptoms were reported to have improved in 70 to 75% of the patients. Only mild adverse events were reported during the study.
Conclusion: UDCA can be considered as a safe and effective medication for the improvement of both biochemical and clinical outcomes in chronic liver disease.
Keywords: Chronic liver disease, Ursodeoxycholic acid, ALT, AST, ALP, bilirubin, safety, efficacy
Cite This Article:
Please cite this article in press Chandana Basavaraj Sanadi et al., A Study On Assessment Of Efficacy And Safety Of Ursodeoxycholic Acid In Patients With Chronic Liver Disease, Indo Am. J. P. Sci, 2025; 12(11).
REFERENCES:
1. De Siervi S, Cannito S, Turato C. Chronic Liver Disease: Latest Research in Pathogenesis, Detection and Treatment. Int J Mol Sci. 2023 Jun 25;24(13):10633.
2. Heidelbaugh JJ, Bruderly M. Cirrhosis and chronic liver failure: part I. Diagnosis and evaluation. Am Fam Physician. 2006 Sep 01;74(5):756-62.
3. Gan C, Yuan Y, Shen H, Gao J, Kong X, Che Z, Guo Y, Wang H, Dong E, Xiao J. Liver diseases: epidemiology, causes, trends and predictions. Signal Transduct Target Ther. 2025 Feb 5;10(1):33.
4. Wazir H, Abid M, Essani B, Saeed H, Ahmad Khan M, Nasrullah F, Qadeer U, Khalid A, Varrassi G, Muzammil MA, Maryam A, Syed ARS, Shah AA, Kinger S, Ullah F. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus. 2023 Dec 4;15(12):e49920
5. Halder P, Roy S, Banerjee S, Mandal S, Das K, Chowdhury A, Mahiuddin Ahammed S. Clinical Profile and Prognostic Markers of Acute on Chronic Liver Failure (ACLF): A Single-center Experience from East India. J Clin Exp Hepatol. 2023 Nov-Dec;13(6):1017-1024
6. Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol. 2001 Jul;35(1):134-46
7. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002 Sep;36(3):525-31
8. Oh B, Choi WS, Park SB, Cho B, Yang YJ, Lee ES, Lee JH. Efficacy and safety of ursodeoxycholic acid composite on fatigued patients with elevated liver function and/or fatty liver: a multi-centre, randomised, double-blinded, placebo-controlled trial. Int J Clin Pract. 2016 Apr;70(4):302-11.
9. Leuschner U, Fischer H, Kurtz W, et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double‐blind trial. Gastroenterology 1989; 97: 1268–74.
10. Kong X, Kong Y, Zhang F, Wang T, Yan J. Evaluating the effectiveness and safety of ursodeoxycholic acid in treatment of intrahepatic cholestasis of pregnancy: A meta-analysis (a prisma-compliant study). Medicine (Baltimore). 2016 Oct;95(40):e4949.
11. Simental-Mendía M, Sánchez-García A, Simental-Mendía LE. Effect of ursodeoxycholic acid on liver markers: A systematic review and meta-analysis of randomized placebo-controlled clinical trials. Br J Clin Pharmacol. 2020 Aug;86(8):1476-1488.
12. Patel VS, Mahmood SF, Bhatt KH, Khemkar RM, Jariwala DR, Harris B, George MM, Kurudamannil RA, Anyagwa OE, Tak RS, Kassem M. Ursodeoxycholic Acid’s Effectiveness in the Management of Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Euroasian J Hepatogastroenterol. 2024 Jan-Jun;14(1):92-98.
13. Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy. Gastroenterology. 2005 Sep;129(3):894-901.
14. Ratziu V, de Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, Sogni P, Maynard M, Larrey D, Serfaty L, Bonnefont-Rousselot D, Bastard JP, Rivière M, Spénard J; FRESGUN. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011 May;54(5):1011-9
15. Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet. 1999 Sep 25;354(9184):1053-60
16. Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. N Engl J Med. 1994 May 12;330(19):1342-7.